Go to the list of all blogs
published in Blogs
Jul 15, 2026
Chime Financial (CHYM) +28.5% Rally Over 30 Days: Key Drivers Behind the Move

Chime Financial (CHYM) +28.5% Rally Over 30 Days: Key Drivers Behind the Move

Key Takeaways

  • Chime Financial (CHYM) surged approximately 28.5% over the last 30 days, climbing from $16.70 on June 12 to $21.46 by July 14, 2026.
  • The rally was fueled by Russell index inclusion, a bullish Barclays initiation, and sustained momentum from the company's first-ever GAAP-profitable quarter reported in May.
  • Over the broader quarter, the stock staged a sharp recovery after hitting its 52-week low of $15.88 on June 11, powered by improving fundamentals and renewed institutional interest.
  • Analyst consensus stands at Moderate Buy with an average 12-month price target near $29.65, implying roughly 38% upside from recent levels.
  • Key risks include elevated competitive pressure in digital banking, insider selling activity, and ongoing GAAP net losses on a trailing-twelve-month basis despite quarterly profitability.

Chime Financial (CHYM) Company Background and Positioning

Chime Financial, Inc. is a San Francisco-based fintech company offering mobile-first banking services that aim to cut fees and streamline daily transactions. Founded in 2013, it runs a digital platform with spending accounts, savings accounts, debit cards, and credit-building tools, all free of monthly maintenance fees, overdraft charges, or foreign transaction fees. Revenue comes mainly from interchange fees on debit and credit card activity rather than direct customer charges.

The company has grown to more than 10.2 million active members as of Q1 2026 and was ranked the #1 financial institution for new checking account openings in the U.S. by J.D. Power. Core offerings include the Chime Card secured credit product, MyPay earned wage access, Instant Loans, and the new Chime Prime premium membership. It went public in June 2025 at $27 per share and trades on Nasdaq as CHYM.

CHYM Stock Performance: The Last 30 Days and the Quarter

CHYM posted a strong 30-day advance, moving from a June 12, 2026 close of $16.70 to $21.46 on July 14, 2026, for a gain of roughly 28.5%. That move stands out because the stock had touched its 52-week low of $15.88 just the day before on June 11, so the rebound from trough to the July 14 close exceeded 35%.

The catalyst arrived on June 26, when shares jumped about 11% in one session to $20.32 on more than double normal volume after news that Chime would join several Russell indexes. In the weeks that followed, the stock held in the $20.50–$21.50 range, supported by a positive Barclays initiation and steady buying interest. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Over the full quarter the path was uneven. Through mid-June the shares slipped from the $18–$19 area in late May down to the $15.88 low amid broader fintech volatility and insider-selling headlines. Since that bottom, however, CHYM has recovered sharply, erasing the quarterly losses and turning modestly positive versus late-April levels on the back of revenue growth, margin expansion, and the first GAAP-profitable quarter.

What Fueled the 30-Day Advance

Several factors came together in a short period. First, inclusion in major Russell indexes around June 26 triggered buying from index funds and ETFs, producing the highest single-day volume in the post-IPO history with more than 22 million shares traded on June 26 alone.

Second, on July 8 Barclays started coverage with an Overweight rating and a $26 price target, pointing to Chime’s durable position and monetization potential after the sector reset. That added to an already constructive analyst picture: of 19 covering analysts, 14 rate the stock Buy or Strong Buy, with Morgan Stanley, Wells Fargo, and BMO Capital among the supporters.

Third, investors continued to absorb the milestone Q1 2026 results released May 6. Chime delivered its first GAAP-profitable quarter as a public company, posting $53 million in net income, $647 million in revenue (up 25% year-over-year), and $119 million in adjusted EBITDA (18% margin). Management lifted full-year revenue guidance to $2.66–$2.69 billion and authorized an extra $200 million for share repurchases.

Other supports included the rollout of Chime Prime with enhanced rewards and yields, growing adoption of the Chime Card (now roughly 25% of purchase volume), and strong scaling of MyPay, which is running at more than $400 million in annualized revenue. Institutional interest also rose, with HSBC Holdings reporting a new position of about 49,866 shares in a recent 13F filing.

Quarterly Performance Context and Fundamentals

Over the past quarter CHYM’s move reflects a shift from post-IPO revaluation pressures to a fundamentals-driven recovery. Early in the period the stock faced headwinds from high short interest, insider sales—including two June transactions by General Counsel Adam B. Frankel totaling 6,000 shares—and broader risk-off sentiment in growth fintech names, pushing the price to the $15.88 low.

The turn came as investors focused on improving unit economics and discounted valuation. Q1 results showed operating leverage: transaction margin reached 76%, incremental adjusted EBITDA margin hit 73%, and the ChimeCore platform delivered cost efficiencies. AI-assisted development now accounts for 84% of shipped code, supporting faster product releases without added headcount. Together with the Russell index catalyst, these improvements created a credible floor and powered the recovery through July.

Using Data-Driven Tools to Track Momentum

One resource I’ve found helpful when monitoring stocks like CHYM is Tickeron’s Trending AI Robots. It highlights a selection of top-performing algorithmic trading bots across various strategies, from short-term momentum to longer-term trend models, each with transparent performance metrics and trade histories. Exploring the page can help match automated approaches to individual trading preferences and risk levels.

Key Items to Watch Going Forward

The next major catalyst is the Q2 2026 earnings report, expected around August 6, 2026. Management guided Q2 revenue of $633–$643 million with adjusted EBITDA margins of 11–12%, and investors will watch for a second straight quarter of GAAP profitability.

Other areas of focus include the pace of Chime Card adoption and its effect on take rates, progress on Chime Enterprise partnerships such as the upcoming integration with First Student and its more than 65,000 employees, and continued growth in MyPay and Instant Loans originations with stable loss rates. Broader factors like consumer spending, Federal Reserve policy, and potential interchange-fee regulation also matter. With short interest at 4.33% of the float, further upside could bring additional short-covering support.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CHYM

CHYM's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CHYM turned positive on July 31, 2026. Looking at past instances where CHYM's MACD turned positive, the stock continued to rise in of 7 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on CHYM as a result. In of 18 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHYM advanced for three days, in of 52 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 29 cases where CHYM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHYM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CHYM broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.673) is normal, around the industry mean (28.717). P/E Ratio (5.993) is within average values for comparable stocks, (82.489). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.745). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (5.063) is also within normal values, averaging (77.023).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Datadog (NASDAQ:DDOG), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 10.47B. The market cap for tickers in the group ranges from 291 to 234.43B. SAP holds the highest valuation in this group at 234.43B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 4%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 11%. TEAM experienced the highest price growth at 51%, while NXTT experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was -21%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was -41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 76
Price Growth Rating: 56
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
CHYM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Profile
Details
Interact to see
Advertisement
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.